Correspondence

Benefit v. risk when using chloroquine in patients with severe COVID-19 disease

E H Decloedt, H Reuter, B Allwood, A Parker, C F N Koegelenberg, M Blockman, J Taljaard

Abstract


-

Authors' affiliations

E H Decloedt, Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

H Reuter, Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

B Allwood, Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

A Parker, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

C F N Koegelenberg, Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

M Blockman, Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa

J Taljaard, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

Full Text

PDF (64KB)

Cite this article

South African Medical Journal 2020;110(5):336. DOI:10.7196/SAMJ.2020.v110i5.14761

Article History

Date submitted: 2020-04-02
Date published: 2020-04-02

Article Views

Abstract views: 864
Full text views: 234

Comments on this article

*Read our policy for posting comments here